Table 5.

Multivariate Cox hazards analysis for progression-free survival in EGFR-TKI-treated patients

Characteristics	Number	Model 1			Model 2
		HR	95% CI	P-value	HR	95% CI	P-value
Sex
Male vs female	27 vs 48	0.865	0.462–1.617	0.649	1.174	0.615–2.242	0.626
Smoking history
Yes vs no	12 vs 63	2.039	0.899–4.625	0.088	1.243	0.522–2.959	0.623
Performance status
0–1 vs 2	48 vs 27	1.456	0.866–2.446	0.156	1.419	0.827–2.433	0.204
HDL-C (mmol/L)
≤0.945 vs >0.945	28 vs 47	0.126	0.064–0.247	<0.001
HDL-C kinetics
Nondecreased	29				0.003	0.001–0.018	<0.001
Normalized	19				0.13	0.002–0.068	<0.001
Decreased	16				0.029	0.006–0.152	<0.001
Nonnormalized	11

Notes: The multivariate Cox hazards analysis for model 1 includes sex, smoking history, performance status and baseline HDL-C, while the model 2 includes sex, smoking history, performance status and HDL-C kinetics. The baseline HDL-C and HDL-C kinetics are the main difference between model 1 and model 2.

Abbreviations: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; HR, hazard ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol.